Get the Stockscreener App
0.7069
7.77%
0.0504
After Hours:
.69
-0.0169
-2.39%
Sangamo Therapeutics Inc stock is traded at $0.7069, with a volume of 19.29M.
It is up +7.77% in the last 24 hours and down -31.97% over the past month.
See More
Previous Close:
$0.6565
Open:
$0.6
24h Volume:
19.29M
Relative Volume:
2.71
Market Cap:
$147.52M
Revenue:
$52.29M
Net Income/Loss:
$-134.84M
P/E Ratio:
-0.9425
EPS:
-0.75
Net Cash Flow:
$-117.11M
1W Performance:
+7.88%
1M Performance:
-31.97%
6M Performance:
-11.81%
1Y Performance:
+26.07%
1-Day Range:
$0.525
$0.715
1-Week Range:
$0.525
$0.7651
52-Week Range:
$0.304
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Name
Sangamo Therapeutics Inc
Sector
Industry
Phone
(510) 970-6000
Address
501 CANAL BLVD., RICHMOND, CA
Compare SGMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.7069 | 147.52M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 32.85B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 28.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Upgrade | Truist | Hold → Buy |
| Dec-10-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-28-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-21 | Resumed | Guggenheim | Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Dec-16-20 | Resumed | H.C. Wainwright | Buy |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | SunTrust | Buy |
| Aug-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-18 | Initiated | Guggenheim | Buy |
| Jun-20-18 | Initiated | BofA/Merrill | Buy |
| Nov-15-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Nov-01-16 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Oct-23-15 | Resumed | Jefferies | Buy |
| May-03-13 | Initiated | BioLogic Equity Research | Sell |
| Feb-23-11 | Reiterated | JMP Securities | Mkt Outperform |
| Jul-29-10 | Reiterated | Wedbush | Outperform |
| Oct-19-09 | Initiated | Brean Murray | Sell |
| Oct-07-09 | Reiterated | Leerink Swann | Outperform |
| Aug-25-09 | Reiterated | JMP Securities | Mkt Outperform |
View All
Sangamo Therapeutics Inc Stock (SGMO) Latest News
Lilly, Sangamo Enter Capsid License Agreement - Contract Pharma
Another rebound as Sangamo inks $1.4B capsid deal with Lilly - BioWorld MedTech
Lilly Licenses Sangamo’s Capsid Technology For CNS Gene Therapy - insights.citeline.com
Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal (SGMO) - Seeking Alpha
Sangamo Thera enters critical deal with Lilly - The Pharma Letter
Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+ - BioSpace
Lilly throws lifeline to Sangamo with $1.4bn licensing deal - Pharmaphorum
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga
RH, FIVE, SGMO, BAC, TSLA: Top 5 Trending Stocks TodayFive Below (NASDAQ:FIVE), Bank of America (NYSE:BAC) - Benzinga
Sangamo Therapeutics (SGMO) Signs Major Licensing Deal with Eli Lilly - GuruFocus
Sangamo Therapeutics (SGMO) Surges on Licensing Deal with Eli Li - GuruFocus
Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal By Investing.com - Investing.com South Africa
Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal - Investing.com Canada
Struggling Sangamo's brain-penetrating drug delivery tech attracts Eli Lilly in potential $1.4 billion pact - The Business Journals
Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System - MarketScreener
Sangamo Therapeutics Stock Surges After The Bell: What's Going On? - Benzinga
Sangamo Signs Capsid License Deal With Eli Lilly; Shares Rise After Hours - MarketScreener
Sangamo Therapeutics stock soars on Lilly licensing deal By Investing.com - Investing.com South Africa
Sangamo Therapeutics stock soars on Lilly licensing deal - Investing.com India
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System - Business Wire
10 Promising Biotech Stocks to Invest in (April 2025) - Securities.io
Hunter Syndrome Treatment Market Generated Opportunities, - openPR.com
Fabry Disease Market Growth Projections 2023-2032: DelveInsight Analysis | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart
Fabry Disease Market Growth Projections 2023-2032: - openPR
Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress By Investing.com - Investing.com South Africa
Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress - Investing.com India
Truist Removes Price Target From Sangamo Therapeutics, Keeps Buy Rating; Price Target Had Been $5 - MarketScreener
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - Zenopa
8 Analysts Assess Sangamo Therapeutics: What You Need To Know - Benzinga
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2024 Earnings Call Transcript - Insider Monkey
US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being' - Benzinga
IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo
Sangamo Therapeutics shares fall as Q4 results miss estimates - Investing.com India
Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus.com
Earnings call transcript: Sangamo Therapeutics Q4 2024 reveals minor EPS miss By Investing.com - Investing.com South Africa
Sangamo: Q4 Earnings Snapshot - mySA
Earnings call transcript: Sangamo Therapeutics Q4 2024 reveals minor EPS miss - Investing.com
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Sangamo Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sangamo Therapeutics Q4 2024 Earnings: EPS of -$0.11 Misses Esti - GuruFocus.com
Sangamo: Q4 Earnings Snapshot -March 17, 2025 at 04:36 pm EDT - Marketscreener.com
Sangamo Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Sangamo Therapeutics shares fall as Q4 results miss estimates By Investing.com - Investing.com Australia
SANGAMO THERAPEUTICS, INC SEC 10-K Report - TradingView
Sangamo Therapeutics earnings missed, revenue fell short of estimates - Investing.com UK
SANGAMO THERAPEUTICS Earnings Preview: Recent $SGMO Insider Trading, Hedge Fund Activity, and More - Nasdaq
SBI Securities Co. Ltd. Invests $28,000 in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference - Zenopa
Sangamo Therapeutics Inc Stock (SGMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):